Roth Capital Raises Earnings Estimates for Gain Therapeutics

Gain Therapeutics, Inc. (NASDAQ:GANX) – Analysts at Roth Capital upped their FY2025 EPS estimates for Gain Therapeutics in a research report issued on Wednesday, November 12th. Roth Capital analyst B. Pachaiyappan now forecasts that the company will earn ($0.64) per share for the year, up from their previous forecast of ($0.69). Roth Capital has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics’ Q4 2025 earnings at ($0.14) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.20) EPS and FY2026 earnings at ($0.62) EPS.

GANX has been the topic of a number of other research reports. Maxim Group boosted their target price on shares of Gain Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, October 7th. BTIG Research reiterated a “buy” rating and set a $9.00 price objective on shares of Gain Therapeutics in a research note on Wednesday, October 15th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a report on Monday, October 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.86.

Gain Therapeutics Stock Up 1.1%

GANX opened at $2.85 on Monday. The company has a 50 day moving average of $1.98 and a 200 day moving average of $1.84. The company has a market cap of $103.29 million, a PE ratio of -4.67 and a beta of 0.13. Gain Therapeutics has a 12 month low of $1.41 and a 12 month high of $3.06. The company has a current ratio of 2.52, a quick ratio of 2.52 and a debt-to-equity ratio of 0.05.

Gain Therapeutics (NASDAQ:GANX) last posted its earnings results on Wednesday, November 12th. The company reported ($0.15) earnings per share for the quarter, hitting the consensus estimate of ($0.15).

Hedge Funds Weigh In On Gain Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Dauntless Investment Group LLC purchased a new stake in shares of Gain Therapeutics during the 1st quarter valued at $240,000. Kovitz Investment Group Partners LLC purchased a new stake in Gain Therapeutics during the first quarter valued at about $91,000. Geode Capital Management LLC lifted its stake in Gain Therapeutics by 2.9% during the second quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock worth $523,000 after purchasing an additional 8,251 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Gain Therapeutics by 41.0% in the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock worth $498,000 after purchasing an additional 80,407 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC bought a new position in shares of Gain Therapeutics during the 3rd quarter valued at about $28,000. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.